
Takeda announced FDA approval of EOHILIA (budesonide oral suspension), the first FDA-approved oral therapy for people aged 11 and above with eosinophilic esophagitis (EoE). Available in 2 mg/10 mL single-dose stick packs by February end, EOHILIA, a corticosteroid, is indicated for 12 weeks of treatment in EoE patients. Its unique formulation offers thixotropic properties. FDA approval is based on efficacy and safety data from two 12-week studies. Common adverse reactions include respiratory tract infection, gastrointestinal mucosal candidiasis, and headache. Takeda anticipates the financial impacts of approval to be immaterial.
Like
Save
Share